HDAC9 and melanoma: The addition of HDAC inhibitor VPA prior (but not concurrently) to virus infection increased virus replication and cytotoxity in human melanoma cells, increased NK ligand expression on melanoma cells and NK cell killing, and CTL priming against melanoma TAAs, all markers of anti-tumor immunity [179].